It's timely, because Pharmac is just reviewing the rare disorders program after five years and invested around $25 million. I think it has 10 medicines that it has put through. Not to be critical, but in one case I'm aware of, the medicine they approved for funding actually has no New Zealand patients, so no one is actually eligible to get this medicine for a rare disorder in New Zealand.
Young patients are eligible, but at the moment we don't have any young patients with this particular rare disease. It was modelled, I think, on the Scottish rare disease fund, so it's a separate amount of money, but when someone inquired under an official information act request to Pharmac, they found out that the money wasn't referenced for that fund at all.
They're just reviewing that fund at the moment. As Heather said, it's quite full, because the medicines are quite expensive. It's not for a lot of people, and Pharmac buys on behalf of the entire population of the community of New Zealand.